EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold

Gabriel Bsteh iD, Harald Hegen, Nik Krajnc iD, Fabian Föttinger, Patrick Altmann iD, Michael Auer, Klaus Berek, Barbara Kornek iD, Fritz Leutmezer, Stefan Macher iD, Tobias Monschein, Markus Ponleitner und 9 weitere

Annals of Clinical and Translational Neurology · 2025-02 · 12 (2) · 345-354

DOI: 10.1002/acn3.52279 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 16.12.2024. Verfasst von Gabriel Bsteh und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Retina, Immunologic Factors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Austrian MS Research Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate retinal layer thinning as a biomarker of disease‐modifying treatment (DMT) effects in relapsing multiple sclerosis (RMS).

Methods

From an ongoing prospective observational study, we included patients with RMS, who (i) had an optical coherence tomography (OCT) scan within 6 to 12 months after DMT start (rebaseline) and ≥1 follow‐up OCT ≥12 months after rebaseline and (ii) adhered to DMT during follow‐up. Differences between DMT in thinning of peripapillary‐retinal‐nerve‐fiber‐layer (pRNFL) and macular ganglion cell‐plus‐inner plexiform‐layer (GCIPL) were analyzed using mixed‐effects linear regression. Eyes suffering optic neuritis during follow‐up were excluded.

Results

We included 291 RMS patients (mean age 30.8 years [SD 7.9], 72.9% female, median disease duration 9 months [range 6–94], median rebaseline‐to‐last‐follow‐up‐interval 32 months [12–82]). Mean annualized rates of retinal layer thinning (%/year) in reference to DMF ( n = 84, GCIPL 0.28, pRNFL 0.53) were similar under TERI ( n = 18, GCIPL 0.34, pRNFL 0.59), GLAT ( n = 24, GCIPL 0.32, pRNFL 0.56), and IFNb ( n = 13, GCIPL 0.33, pRNFL 0.60) were slightly lower under S1PM ( n = 27, GCIPL 0.19, pRNFL 0.42) and CLA ( n = 23, GCIPL 0.20, pRNFL 0.42), and were significantly lower under NTZ ( n = 47, GCIPL 0.09, pRNFL 0.24; both p < 0.001) and antiCD20 ( n = 55, GCIPL 0.10, pRNFL 0.23; both p < 0.001). In patients achieving NEDA‐2, observed thinning rates were lower overall, but still significantly lower under NTZ and antiCD20.

Interpretation

Applying a rebaselining concept, retinal layer thinning differentiates DMT effects even in clinically stable patients and, thus, might be a useful biomarker to monitor DMT efficacy on subclinical neuroaxonal degeneration—at least on a group level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingRetinaImmunologic FactorsHumansFemaleMaleTomography, Optical CoherenceAdultProspective StudiesYoung AdultMiddle AgedFollow-Up Studies

Substanzen

Immunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
  • Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Gabriel Bsteh, Nik Krajnc, Patrick Altmann, Barbara Kornek, Stefan Macher, Tobias Zrzavy, Berthold Pemp

Förderung

  • Austrian MS Research Society

Zitieren

APA

Bsteh, G., Hegen, H., Krajnc, N., Föttinger, F., Altmann, P., Auer, M., Berek, K., Kornek, B., Leutmezer, F., Macher, S., Monschein, T., Ponleitner, M., Rommer, P., Schmied, C., Zebenholzer, K., Zulehner, G., Zrzavy, T., Deisenhammer, F., Di Pauli, F., …, & Berger, T. (2025). Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold. Annals of Clinical and Translational Neurology, 12(2), 345-354. https://doi.org/10.1002/acn3.52279

Vancouver

Bsteh G, Hegen H, Krajnc N, Föttinger F, Altmann P, Auer M, et al. Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold. Annals of Clinical and Translational Neurology. 2025;12(2):345-354. doi:10.1002/acn3.52279

BibTeX
@article{Bsteh2025,
  author = {Bsteh, Gabriel and Hegen, Harald and Krajnc, Nik and Föttinger, Fabian and Altmann, Patrick and Auer, Michael and Berek, Klaus and Kornek, Barbara and Leutmezer, Fritz and Macher, Stefan and Monschein, Tobias and Ponleitner, Markus and Rommer, Paulus and Schmied, Christiane and Zebenholzer, Karin and Zulehner, Gudrun and Zrzavy, Tobias and Deisenhammer, Florian and Di Pauli, Franziska and Pemp, Berthold and Berger, Thomas},
  title = {Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  volume = {12},
  number = {2},
  pages = {345--354},
  doi = {10.1002/acn3.52279}
}
Kostenlos starten →